Edition:
United States

ArQule Inc (ARQL.OQ)

ARQL.OQ on NASDAQ Stock Exchange Global Market

2.95USD
4:00pm EDT
Change (% chg)

$-0.18 (-5.75%)
Prev Close
$3.13
Open
$3.11
Day's High
$3.16
Day's Low
$2.92
Volume
225,137
Avg. Vol
129,240
52-wk High
$3.34
52-wk Low
$0.92

Chart for

About

ArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug... (more)

Overall

Beta: 1.20
Market Cap(Mil.): $80.42
Shares Outstanding(Mil.): 71.17
Dividend: --
Yield (%): --

Financials

  ARQL.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -0.39 -- --
ROI: -91.39 1.58 14.38
ROE: -120.33 2.41 16.07

BRIEF-Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib

* ARQULE AND BASILEA ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DERAZANTINIB IN THE US, EU, JAPAN AND REST OF WORLD EXCLUDING GREATER CHINA

Apr 17 2018

BRIEF-ArQule Reports Q4 Loss Per Share $0.09

* ARQULE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 05 2018

BRIEF-Roivant Sciences And Arqule Enter Into License Agreement For Derazantinib In China

* ROIVANT SCIENCES AND ARQULE ENTER INTO LICENSE AGREEMENT FOR DERAZANTINIB IN CHINA

Feb 07 2018

BRIEF-ArQule Files For Offering Of Up To 17.1 Million Shares

* ARQULE INC FILES FOR OFFERING OF UP TO 17.1 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text for Eikon: (http://bit.ly/2ivqMQn) Further company coverage:

Dec 06 2017

BRIEF-Arqule reports dosing in registrational trial of FGFR inhibitor

* Arqule announces dosing in a registrational trial of fgfr inhibitor, derazantinib, for treatment of intrahepatic cholangiocarcinoma

Nov 21 2017

BRIEF-Arqule reports Q3 loss per share $0.09

* Q3 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S

Nov 09 2017

BRIEF-ArQule announces $9.5 mln private placement of preferred stock

* ArQule announces $9.5 million private placement of preferred stock

Nov 08 2017

Earnings vs. Estimates